SBIR/STTR Research Award

Hematopoietic Kits for Osteoclast Formation

Award identifier 5395161418b347f1e3a92561de1f63a33b6e9631fe429b356158e4cf55f49d3dAwarding agency Department of Health and Human Services

Award amount

$452,684

Program and phase

SBIR · Phase II

Award year

1995

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
Not reported
Recipient company
QUALITY BIOLOGICAL, INC.
Proposal award date
Not reported
Contract end date
Not reported
UEI
V7ACWSNAL845
Solicitation number
Not reported
Topic code
Not reported

Research abstract

With the recent isolation and identification of osteoclast progenitors and the isolation andpurification of osteoclast colony stimulating factor, new and exciting avenues of research can now beapproached. The development of chemically defined osteoclast hematopoietic reagents would be ofinestimable importance for gaining specific information concerning phenomena such as the proliferationof osteoclasts and the role which these cells play in the process of hematopoiesis, bone formation, andbone resorption. We will develop an osteoclast/hematopoieticre agents that will support in vitroosteoclasts colony formation. Culture of osteoclast requires the presence of ill-defined components.The research herein will be to develop osteoclast/hematopoietic reagents and the technology to avoidthe use of serum or any other ill-defined component. This reagent will fill the critical void to provideinvestigators who are working in this exciting area. They have preliminary data indicating thatosteoclast/hematopoietic reagents in combination with purified osteoclast colony stimulating factorssupported osteoclast colony formation. However, the reagent formulation needs to be further developedsince it did not support colony formation equivalent to serum containing reagents. This proposal willdevelop osteoclasts/hematopoietic kits and reagent medium for osteoclast proliferation that does notrequire the presence of serum. These reagents will be valuable in assessing the growth parameters ofosteoclast in both normal and diseased states. It also will be of value in assessing the cytokinesinvolved in these processes.

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Research funding history

25 SBIR/STTR records share this UEI (1987–2020). Reported award amounts total $6,768,750. Reported amounts are not federal obligations.

Phases: Phase I, Phase II

Agencies: Department of Health and Human Services, Department of Defense

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.